In this study, researchers from China evaluated preoperative peripheral blood samples for the determination of CEA, CK19, and CK20 mRNA expression.
The team took 62 samples from patients with GI carcinoma, 12 healthy volunteers, and 10 patients with inflammatory GI disease.
The researchers used nested RT-PCR was to analyze CEA, CK19, and CK20 mRNA expression in the peripheral blood samples.
|Only 1 blood sample from patients with no GI cancer was positive for CEA mRNA.|
|Journal of Cancer Research and Clinical Oncology|
Tumor tissues from 15 patients with colorectal cancer were used as a positive control.
The team found that of the samples from patients with GI cancer expression of CEA, CK19, and CK20 mRNA was 52%, 36%, and 48%, respectively. Overall, 74% were positive for at least 1 marker.
They determined that the 15 tumor tissues were all positive for CEA, CK19, and CK20 mRNA.
Furthermore, the team found that only 1 blood sample from patients with no GI carcinoma was positive for CEA mRNA.
Dr Peilin Huang's team concluded, "Molecular detection of circulating tumor cells in peripheral blood in patients with GI carcinoma was significantly correlated with its malignant biological properties".
"And may be helpful in the selection of clinical treatment and judgment of prognosis".